SUMMARY
Hydrocortisone and Acetic Acid Otic Solution, USP is a solution containing hydrocortisone (1%) and acetic acid (2%), in a propylene glycol vehicle containing propylene glycol diacetate (3%), benzethonium chloride (0.02%), sodium acetate (0.015%) and citric acid.
Hydrocortisone and Acetic Acid (hydrocortisone/acetic acid OTIC) is indicated for the following:
For the treatment of superficial infections of the external auditory canal caused by organisms susceptible to the action of the antimicrobial, complicated by inflammation.
|
NEWS HIGHLIGHTSMedia Articles Related to Hydrocortisone and Acetic Acid (Hydrocortisone / Acetic Acid Otic)
Brain Inflammation Tied to Depression, Suicidal Thoughts
Source: Medscape Pathology & Lab Medicine Headlines [2017.09.29]
Animal and postmortem studies point to a link between neuroinflammation and depression and suicidality. This study used PET scans to corroborate these findings in living human beings.
Medscape Medical News
Drug Beats Steroids for Controlling Blood Vessel Inflammation in Study
Source: MedicineNet Clinical Trials Specialty [2017.07.27]
Title: Drug Beats Steroids for Controlling Blood Vessel Inflammation in Study
Category: Health News
Created: 7/26/2017 12:00:00 AM
Last Editorial Review: 7/27/2017 12:00:00 AM
Balanitis (Inflammation of the Head of the Penis)
Source: MedicineNet clotrimazole and betamethasone dipropionate Specialty [2016.08.19]
Title: Balanitis (Inflammation of the Head of the Penis)
Category: Diseases and Conditions
Created: 6/24/2013 12:00:00 AM
Last Editorial Review: 8/19/2016 12:00:00 AM
Prostatitis (Inflammation of the Prostate Gland)
Source: MedicineNet finasteride Specialty [2016.08.17]
Title: Prostatitis (Inflammation of the Prostate Gland)
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 8/17/2016 12:00:00 AM
Psoriasis Patients Face Increased Risk of Heart Attacks and Death
Source: Medscape Medical News Headlines [2017.09.29]
People with psoriasis, a chronic inflammatory disease, may be more likely than others to experience heart attacks and strokes at least in part because inflammation damages their vascular system, a recent study suggests.
Reuters Health Information
Published Studies Related to Hydrocortisone and Acetic Acid (Hydrocortisone / Acetic Acid Otic)
Effects of sucralfate, lansoprazole, and cimetidine on the delayed healing by hydrocortisone sodium phosphate of chronic gastric ulcers in the rat. [1991.08.08]
We have previously shown that chronic sucralfate ingestion stimulates gastric epithelial proliferation in rats, which may explain one of the beneficial effects of sucralfate in healing of peptic ulcers. In a separate study, we have found that chronic steroid administration delays the healing of experimental gastric ulcers in rats...
Effects of prostaglandins on hydrocortisone-induced delayed healing of chronic gastric ulcers in the rat. [1991]
We have previously shown that chronic steroid administration delays the healing of experimental gastric ulcers in rats. This study was designed to test the beneficial effects of 16,16-dimethylprostaglandin E2 or TRY-200, a stable prostaglandin I2 analogue, on the delayed healing by hydrocortisone (HC) of chronic gastric ulcers in rats...
Kinetics of drug release from polylactic acid-hydrocortisone microcapsules. [1986.07]
Polylactic acid microcapsules of similar particle size distribution containing various drug loadings of hydrocortisone were prepared. The microcapsules, which contained randomly dispensed drug particles, showed a dissolution pattern which consists of a fast first-stage and a slow second-stage drug release.
Clinical Trials Related to Hydrocortisone and Acetic Acid (Hydrocortisone / Acetic Acid Otic)
The Influence of Different Hydrocortisone Replacement Doses on the Partitioning and Flexibility of Ectopic Lipids in Patients With Corticotropic Hypopituitarism [Recruiting]
This study aims at assessing the effect of today's standard of hydrocortisone dosage versus
previous hydrocortisone dosage on flexibility and partitioning of ectopic lipid depots (IMCL
and IHCL) after a standardised fat load followed by a short-term aerobic exercise in
patients with corticotropic pituitary insufficiency.
Once-daily Oral Modified Release Hydrocortisone in Patients With Adrenal Insufficiency [Completed]
This is a randomised, controlled, open, two-armed, two-period cross-over, multi-centre phase
II/III study to assess the safety, tolerability and pharmacokinetics of once-daily oral
modified-release hydrocortisone in comparison to conventional thrice-daily oral
hydrocortisone tablets in patients with adrenal insufficiency
Ultradian Subcutaneous Hydrocortisone Infusion in Addison Disease and Congenital Adrenal Hyperplasia [Recruiting]
Effect of Slow Release Hydrocortisone on Fed & Fasting Volunteers; Immediate Release on Fasting Only [Completed]
The purpose of the study is to find out whether food has an effect on the way the body deals
with modified release hydrocortisone, and to compare with the pharmacokinetics of
immediate release hydrocortisone (fasted). This information will be used to help doctors
with dosing in clinical practice.
Modified-release Compared to Conventional Hydrocortisone on Diurnal Fatigue in Secondary Hypoadrenalism [Enrolling by invitation]
Despite optimized hydrocortisone replacement regimes, many patients with adrenal
insufficiency (AI) suffer from impaired quality of life (QoL). Characteristically, patients
report high fatigue levels at certain times during the day. A modified-release
hydrocortisone has been shown to improve QoL, particularly fatigue, in patients with primary
AI. However, it is unknown, if the same effect can be observed in patients with secondary
AI. Further, no studies have evaluated the effect, taking into account the diurnal variation
of fatigue. A novel survey method termed Ecological Momentary Assessments (EMA) has the
potential to provide reliable measurements of diurnal variations in patient-reported
outcomes, such as fatigue. We will compare the effect of modified-release compared to
conventional hydrocortisone on fatigue in patients with secondary AI due to pituitary
disease, and hereby assess the feasibility of EMA as outcome in future large-scale
randomised clinical trials (RCTs).
|
